Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GlaxoSmithKline ( (GB:GSK) ) has issued an announcement.
GSK has repurchased 330,000 of its ordinary shares on 8 April 2026 via BNP Paribas under its existing share buyback programme, paying a volume-weighted average price of 2,125.45p per share, with the stock to be held in treasury. The transaction lifts total buybacks since 17 February 2026 to 17,566,521 shares and leaves GSK with 257,457,615 shares in treasury, representing 6.34% of voting rights, and 4,058,726,834 voting shares in issue, information that helps investors gauge ownership thresholds and disclosure obligations.
The company also detailed that the latest buyback takes place across London Stock Exchange and Cboe Europe venues, underscoring the ongoing execution of its capital return strategy. By concentrating repurchased shares in treasury rather than cancelling them, GSK preserves flexibility for future capital management actions, while the clarified voting-rights denominator guides shareholders in monitoring changes to their reportable stakes under U.K. transparency rules.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company focused on developing, manufacturing and commercializing prescription medicines, vaccines and consumer healthcare products. The group operates across multiple therapeutic areas and derives the majority of its revenue from large international markets, with its shares listed in London and included in major U.K. equity indices.
Average Trading Volume: 9,544,858
Technical Sentiment Signal: Buy
Current Market Cap: £83.77B
See more insights into GSK stock on TipRanks’ Stock Analysis page.